Diagnosis and treatment of chronic Helicobacter pylori-associated gastritis: achievements and what hinders further success?

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article presents information on the current state of chronic Helicobacter pylori-associated gastritis. Key pathogenetic, clinical, diagnostic, and therapeutic aspects of the disease are systematized. The choice of diagnostic methods for H. pylori is substantiated. The growing problem of antibiotic resistance in bacteria is noted. First- and subsequent-line eradication therapy regimens are analyzed. Future prospects for the treatment and prevention of H. pylori gastritis are identified.

About the authors

Olga P. Dudanova

Petrozavodsk State University

Author for correspondence.
Email: odudanova@gmail.com
ORCID iD: 0000-0003-2613-5694
SPIN-code: 6034-5892

Doctor of Medical Sciences, Professor, Head of the Department of Propaedeutics of Internal Diseases and Hygiene, Professor A.P. Zilber Medical Institute

Russian Federation, Petrozavodsk

References

  1. Ивашкин В.Т., Лапина Т.Л., Маев И.В. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации, Научного сообщества по содействию клиническому изучению микробиома человека, Российского общества профилактики неинфекционных заболеваний, Межрегиональной ассоциации по клинической микробиологии и антимикробной химиотерапии по диагностике и лечению H. pylori у взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2022; 32 (6): 72–93. [Ivashkin V.T., Lapina T.L., Maev I.V., et al. Clinical Guidelines of the Russian Gastroenterological Association, Scientific Society for the Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, and Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy on the Diagnosis and Treatment of H. pylori in Adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 32 (6): 72–93.] https://doi.org/10.22416/1382-4376-2022-32-6-72-93.
  2. Лазебник Л.Б., Дехнич Н.Н., Ситкин С.И. и др. Helicobacter pylori, хеликобактериоз и ассоциированные заболевания (VIII Московские соглашения по диагностике и лечению хеликобактериоза у взрослых и детей). Руководство для врачей. Экспериментальная и клиническая гастроэнтерология. 2024 (12): 49–145.. [Lazebnik L.B., Dekhnich N.N., Sitkin S.I., et al. Helicobacter pylori, Helicobacteriosis, and Associated Diseases (VIII Moscow Agreements on the Diagnosis and Treatment of Helicobacteriosis in Adults and Children). A Guide for Physicians. Experimental and Clinical Gastroenterology. 2024 (12): 49–145.] doi: 10.31146/1682-8658-ecg-232-12-49-145.
  3. Sugano K., Tack J., Kuipers E.J. Et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015 Sep; 64 (9): 1353–1367. doi: 10.1136/gutjnl-2015-309252.
  4. Shey W.D., Howden C.W., Moss S.F. et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024; 119: 1730–1753. doi: 10.14309/ajg.0000000000002968; published online September 4, 2024.
  5. Бордин Д.С., Кузнецова Е.С., Стаувер Е.Е. и др. Эпидемиология инфекции Helicobacter pylori в Российской Федерации с 1990 по 2023 г.: систематический обзор. РМЖ. Медицинское обозрение. 2024; 8 (5): 260–267. [Bordin D.S., Kuznetsova E.S., Stauver E.E., et al. Epidemiology of Helicobacter pylori Infection in the Russian Federation from 1990 to 2023: A Systematic Review. RMJ. Medical Review. 2024; 8 (5): 260–267.] doi: 10.32364/2587-6821-2024-8-5-3.
  6. Андреев Д.Н., Хурматуллина А.Р., Бордин Д.С. и др. Динамика распространённости инфекции Helicobacter pylori у взрослого населения Москвы: систематический обзор и метаанализ. Терапевтический архив. 2025; 97 (5): 463–470. [Andreev D.N., Khurmatullina A.R., Bordin D.S. et al. Dynamics of Helicobacter pylori Infection Prevalence Among the Adult Population of Moscow: A Systematic Review and Meta-Analysis. Therapeutic Archive. 2025; 97 (5): 463–470.] doi: 10.26442/00403660.2025.05.203250.
  7. Duan M., Li Y., Jing Liu J. et al. Transmission routes and patterns of Helicobacter pylori. Helicobacter. 2023; 28 (1): e12945.
  8. Parsonnet J., Hansen S, Rodriguez L. et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med. 1994; 330 (18): 1267–1271. doi: 10.1056/NEJM199405053301803.
  9. Duan Y., Hu Y., Dou Yi. et al. Helicobacter pylori and gastric cancer: mechanisms and new perspectives. J Hematol Oncol. 2025; 18 (1): 10. doi: 10.1186/S13045-024-01654-2.
  10. Gravina A.G., Zagari R.M., De Musis C. et al. Helicobacter pylori and extragastric diseases: A review. World J Gastroenterol. 2018 Aug 7; 24 (29): 3204–3221. doi: 10.3748/wjg.v24.i29.3204.
  11. Tsay F.W., Hsu P.I. H. pylori infection and extra-gastroduodenal diseases. J Biomed Sci. 2018 Aug 29; 25 (1): 65. doi: 10.1186/s12929-018-0469-6.
  12. Xu G., Ma S., Dong L. et al. Relationship of Helicobacter pylori Infection with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. Can J Gastroenterol Hepatol. 2023 Jan 25; 2023: 5521239. doi: 10.1155/2023/5521239.
  13. Bordin D.S.; Livzan M.A.; Mozgovoi S.I. et al. Autoimmune Gastritis and Helicobacter pylori Infection: Molecular Mechanisms of Relationship. Int. J. Mol. Sci. 2025, 26, 7737. https://doi.org/10.3390/ijms26167737.
  14. Dixon M.F., Genta R.M., Yardley J.H. et al. Histological classification of gastritis and Helicobacter pylori infection: an agreement at last? The International Workshop on the Histopathology of Gastritis. Helicobacter. 1997; 2 (1): S17–S24. doi: 10.1111/j.1523-5378.1997.06b09.x.
  15. Rugge M., Fassan M., Pizzi M. et al. Operative link for gastritis assessment vs operative link on intestinal metaplasia assessment. World J Gastroenterol. 2011 Nov 7; 17 (41): 4596–4601. doi: 10.3748/wjg.v17.i41.4596.
  16. Le V. Application of Current Image-Enhanced Endoscopy in Gastric Diseases. Clin Endosc. 2021; 54: 477–487. doi: 10.5946/ce.2021.160.
  17. Malfertheiner P., Megraud F., O'Morain C.A. et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017 Jan; 66 (1): 6–30. doi: 10.1136/gutjnl-2016-312288.
  18. Schulz C., Liou J.M., Alboraie M. et al. Helicobacter pylori antibiotic resistance: a global challenge in search of solutions. Gut. 2025 Sep 8; 74 (10): 1561–1570. doi: 10.1136/gutjnl-2025-335523.
  19. Андреев Д.Н., Маев И.В., Кучерявый Ю.А. Резистентность Helicobacter pylori в Российской Федерации: метаанализ исследований за последние 10 лет. Терапевтический архив. 2020; 92 (11): 24–30. [Andreev D.N., Maev I.V., Kucheryavy Y.A. Resistance of Helicobacter pylori in the Russian Federation: A Meta-Analysis of Studies Over the Past 10 Years. Therapeutic Archive. 2020; 92 (11): 24–30.] doi: 10.26442/00403660.2020.11.000795.
  20. Casas Deza D., Alcedo J., Lafuente M. et al. Hp-EuReg investigators. Probiotics Prescribed With Helicobacter pylori Eradication Therapy in Europe: Usage Pattern, Effectiveness, and Safety. Results From the European Registry on Helicobacter pylori Management (Hp-EuReg). Am J Gastroenterol. 2025 Nov 1; 120 (11): 2644–2659. doi: 10.14309/ajg.0000000000003351.
  21. Sousa C., Ferreira R., Azevedo N.F. et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol. 2022 May; 48 (3): 376–396. doi: 10.1080/1040841X.2021.1975643.
  22. Лазебник Успенский Ю.П., Барышникова Н. Lactobacillus reuteri против Helicobacter pylori: эффективность in vitro и in vivo. Врач. 2019. 30 (12): 37–42. [Lazebnik Uspensky Y.P., Baryshnikova N. Lactobacillus reuteri Against Helicobacter pylori: Efficacy In Vitro and In Vivo. Vrach. 2019. 30 (12): 37–42.] doi: 10.29296/25877305-2019-12-10.
  23. Бакулина Н.А., Ильчишина Н.В., Бакулин И.Г. и др. Пробиотики в схемах эрадикации Helicobacter pylori: современные данные и результаты собственного исследования. Consilium medicum. 2019. 21 (8): 58–64. [Bakulina N.A., Ilchishina N.V., Bakulin I.G., et al. Probiotics in Helicobacter pylori Eradication Regimens: Current Data and Results of Own Research. Consilium Medicum. 2019. 21 (8): 58–64.] doi: 10.26442/20751753.2019.8.190584.
  24. Han R.S., Hao J.W., Wang T. et al. Efficacy and safety of triple therapy with vonoprazan for Helicobacter pylori eradication: A multicenter, prospective, randomized controlled trial. World J Gastroenterol. 2025 Jul 28; 31 (28): 109001. doi: 10.3748/wjg.v31.i28.109001.
  25. Huang T.T., Cao Y.X., Cao L. Novel therapeutic regimens against Helicobacter pylori: an updated systematic review. Front Microbiol. 2024 Jun 7; 15: 1418129. doi: 10.3389/fmicb.2024.1418129.
  26. Yan T.L., Wang J.H., Zhu R.K. et al. Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial. Helicobacter. 2025 Jul-Aug; 30 (4): e70056. doi: 10.1111/hel.70056.
  27. Rokkas T., Ekmektzoglou K., Niv Y. et al. Comparative Efficacy and Safety of Potassium-Competitive Acid Blocker-Based Dual, Triple, and Quadruple Regimens for First-Line Helicobacter pylori Infection Treatment: A Systematic Review and Network Meta-Analysis. Am J Gastroenterol. 2025 Apr 1; 120 (4): 787–798. doi: 10.14309/ajg.0000000000003084.
  28. Бакулина Н.В., Пономаренко В.А., Керимова А.Ш. и др. Высокодозовая двойная схема эрадикации Helicobacter pylori: эффективность и безопасность. Терапевтический архив. 2025; 97 (8): 642–650. [Bakulina N.V., Ponomarenko V.A., Kerimova A.Sh., et al. High-Dose Dual Therapy for Helicobacter pylori Eradication: Efficacy and Safety. Therapeutic Archive. 2025; 97 (8): 642–650.] doi: 10.26442/00403660.2025.08.203300.
  29. Sousa C., Ferreira R., Azevedo N.F. et al. Helicobacter pylori infection: from standard to alternative treatment strategies. Crit Rev Microbiol. 2022 May; 48 (3): 376–396. doi: 10.1080/1040841X.2021.1975643.
  30. Saha M., Gupta A., Kunkaliemkar Sh. et al. Nanoemulsion as a promising drug delivery strategy for effective eradication of Helicobacter pylori: current insights. Drug Delivery and Translational Research. 2026; 16: 17–44. https://doi.org/10.1007/s13346-025-01986-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Russkiy Vrach Publishing House